Belgian pharmaceutical company UCB is dropping its development of minzasolmin in patients with Parkinson's' disease after the ORCHESTRA study failed to meet its primary and secondary endpoints.

Based in Greenville, United Community Banks (UCB) is in the Finance sector, and so far this year, shares have seen a price change of 6.99%. The bank holding company is paying out a dividend of $0. ...

United Community Banks has shown improvement in deposits, loans, and income, leading to an upgrade from 'sell' to a soft ...

1 Day UCB 0.00% DJIA -0.37% S&P Mid Cap 400 -0.08% Financial Services -0.23% ...

As part of pharmaphorum’s ‘eye-on-innovation’ series, Paul Tunnah speaks to UCB’s head of innovation, Gregory Miller, about how the company is creating a culture based around ‘design ...

In a report released today, Catherine Mealor from KBW maintained a Hold rating on United Community Banks (UCB – Research Report), with a price target of $36.00. The company’s shares closed ...

Barclays analyst Charles Pitman CFA reiterated a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €240.00. The ...

About United Community Banks, Inc.United Community Banks, Inc. (NYSE: UCB) is the financial holding company for United Community, a top 100 U.S. financial institution that is committed to ...